According to the
American Cancer Society, “lung cancer is by far the leading cause of cancer death among
both men and women; about 1 out of 4 cancer deaths are from lung cancer.
Each year, more people die of lung cancer than of
colon, breast, and prostate cancers combined.” Because lung cancers are
often times terminal, it’s important we find a cure. That is why in 2015,
Roswell Park Cancer Institute made a deal with Cuba’s Center for Molecular Immunology (CIM) to
bring the cancer drug
CIMAVax to the United States for a clinical trial.
Today, CIMAVax was approved by the
Food and Drug Administration (FDA) for clinical trials at Roswell Park and the first trial is scheduled
to begin in 30 days. Roswell announced “this trial will enroll approximately
60 to 90 patients with advanced (Stage IIIB/IV) non-small cell lung cancer
(NSCLC) whose disease has progressed during or after first-line systemic
chemotherapy, including targeted therapy.”
Lung cancer is so deadly because there is an increased risk of the recurrence.
The vaccine was originally developed in Cuba, where lung cancer is one
of the leading causes of death. It targets recurring cancer by generating
a natural protein that tells the immune system to attack a hormone called
epidermal growth factor (EGF). EGF is the driving force behind most recurring cancers. If CIMAVax
works as expected, and the EGF is neutralized, recurring lung cancer will
become much more treatable.
Dr. Candace Johnson, the CEO of Roswell Park stated in a news conference, “the lung
cancer vaccine developed by the Center for Molecular Immunology team represents
a creative, unique approach to treating and perhaps preventing cancer,
and we are enormously proud that Roswell Park expects to be the first
U.S. institution to be able to offer it to select patients.” She
also explained in layman’s terms how the drug works. "The whole
basis for it is that these lung cancer cells are addicted to this growth
factor. They need it to survive. It's like their food. So we're
going to immunize you against producing this growth factor. And every
time a tumor cell needs this growth factor, your immune response is going
to kick in. Stop it and the tumor will die. And it works. That's the
beauty of it."
If you are interested in signing up for this clinical trial at Roswell
Park Cancer Institute, you can see the eligibility requirements at:
Railroad workers who have been exposed to asbestos or diesel exhaust are
at an increased risk of lung cancer. If you or a loved one are a current
or former railroad worker diagnosed with cancer, please
contact us to discuss your legal rights with an experienced railroad injury lawyer.